| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 12 | 2025 | 151 | 4.010 |
Why?
|
| Influenza, Human | 12 | 2025 | 282 | 3.810 |
Why?
|
| Influenza Vaccines | 13 | 2025 | 294 | 3.540 |
Why?
|
| Vaccination | 22 | 2025 | 685 | 3.530 |
Why?
|
| Autism Spectrum Disorder | 11 | 2022 | 159 | 3.210 |
Why?
|
| Pregnancy | 25 | 2025 | 1466 | 2.050 |
Why?
|
| Vaccines | 5 | 2025 | 218 | 1.960 |
Why?
|
| Whooping Cough | 4 | 2022 | 65 | 1.960 |
Why?
|
| Humans | 77 | 2025 | 17376 | 1.820 |
Why?
|
| Autistic Disorder | 5 | 2017 | 100 | 1.710 |
Why?
|
| Infant | 19 | 2025 | 1162 | 1.700 |
Why?
|
| Female | 59 | 2025 | 12444 | 1.680 |
Why?
|
| Measles | 3 | 2022 | 24 | 1.540 |
Why?
|
| Young Adult | 29 | 2025 | 2473 | 1.520 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 4 | 2022 | 62 | 1.500 |
Why?
|
| Vaccination Coverage | 5 | 2025 | 52 | 1.370 |
Why?
|
| California | 23 | 2025 | 2317 | 1.360 |
Why?
|
| Adult | 44 | 2025 | 7529 | 1.350 |
Why?
|
| Immunization Schedule | 5 | 2021 | 124 | 1.300 |
Why?
|
| Child | 18 | 2025 | 2382 | 1.250 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 3 | 2019 | 88 | 1.240 |
Why?
|
| Male | 37 | 2025 | 9843 | 1.140 |
Why?
|
| Hospitalization | 11 | 2025 | 805 | 1.140 |
Why?
|
| Adolescent | 24 | 2025 | 3533 | 0.970 |
Why?
|
| Pregnancy Outcome | 4 | 2025 | 158 | 0.960 |
Why?
|
| Infant, Newborn | 11 | 2025 | 805 | 0.950 |
Why?
|
| Child, Preschool | 13 | 2025 | 1375 | 0.940 |
Why?
|
| Case-Control Studies | 17 | 2023 | 1100 | 0.940 |
Why?
|
| Mumps | 2 | 2020 | 12 | 0.840 |
Why?
|
| Mothers | 3 | 2023 | 103 | 0.810 |
Why?
|
| Retrospective Studies | 19 | 2025 | 2428 | 0.770 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 168 | 0.760 |
Why?
|
| Immunologic Factors | 1 | 2022 | 30 | 0.760 |
Why?
|
| Prenatal Care | 2 | 2020 | 127 | 0.740 |
Why?
|
| Seizures, Febrile | 1 | 2022 | 42 | 0.740 |
Why?
|
| Fever | 3 | 2022 | 54 | 0.740 |
Why?
|
| Vaccines, Combined | 7 | 2023 | 80 | 0.700 |
Why?
|
| Cohort Studies | 12 | 2025 | 2526 | 0.700 |
Why?
|
| Databases, Factual | 2 | 2025 | 306 | 0.680 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2017 | 31 | 0.670 |
Why?
|
| Risk Factors | 11 | 2024 | 3255 | 0.640 |
Why?
|
| Insurance, Health | 2 | 2021 | 175 | 0.630 |
Why?
|
| Breast Neoplasms | 6 | 2016 | 977 | 0.610 |
Why?
|
| Early Diagnosis | 2 | 2019 | 36 | 0.600 |
Why?
|
| Cytokines | 2 | 2019 | 30 | 0.600 |
Why?
|
| Antigens | 1 | 2018 | 7 | 0.580 |
Why?
|
| Infection | 1 | 2018 | 17 | 0.580 |
Why?
|
| United States | 16 | 2025 | 3891 | 0.560 |
Why?
|
| Pregnancy Trimester, First | 1 | 2017 | 41 | 0.540 |
Why?
|
| Chickenpox Vaccine | 4 | 2022 | 91 | 0.530 |
Why?
|
| Developmental Disabilities | 3 | 2019 | 52 | 0.530 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 395 | 0.520 |
Why?
|
| Seasons | 4 | 2025 | 113 | 0.510 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 58 | 0.500 |
Why?
|
| Incidence | 8 | 2024 | 1266 | 0.490 |
Why?
|
| Birth Intervals | 1 | 2015 | 7 | 0.490 |
Why?
|
| Clinical Competence | 1 | 2015 | 93 | 0.480 |
Why?
|
| Hypersensitivity | 1 | 2015 | 18 | 0.470 |
Why?
|
| Middle Aged | 22 | 2025 | 7885 | 0.470 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 20 | 0.460 |
Why?
|
| Physicians | 1 | 2015 | 128 | 0.440 |
Why?
|
| Odds Ratio | 5 | 2023 | 644 | 0.440 |
Why?
|
| Premature Birth | 5 | 2024 | 132 | 0.430 |
Why?
|
| Logistic Models | 5 | 2020 | 884 | 0.390 |
Why?
|
| Aged | 16 | 2025 | 6129 | 0.390 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 18 | 0.390 |
Why?
|
| Risk Assessment | 6 | 2022 | 1079 | 0.380 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2024 | 54 | 0.370 |
Why?
|
| Asthma | 1 | 2015 | 388 | 0.370 |
Why?
|
| Fertilization | 1 | 2011 | 3 | 0.370 |
Why?
|
| Vaccines, Inactivated | 3 | 2020 | 72 | 0.360 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1287 | 0.360 |
Why?
|
| Vaccines, Attenuated | 2 | 2022 | 45 | 0.360 |
Why?
|
| Risk | 5 | 2016 | 498 | 0.350 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1155 | 0.310 |
Why?
|
| Central Nervous System Stimulants | 2 | 2011 | 26 | 0.300 |
Why?
|
| Pregnant Women | 2 | 2021 | 46 | 0.300 |
Why?
|
| RNA, Messenger | 6 | 2023 | 72 | 0.290 |
Why?
|
| Antiviral Agents | 2 | 2025 | 100 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 702 | 0.260 |
Why?
|
| Breast Density | 1 | 2016 | 31 | 0.250 |
Why?
|
| Ambulatory Care | 3 | 2022 | 228 | 0.250 |
Why?
|
| Aged, 80 and over | 8 | 2022 | 1942 | 0.250 |
Why?
|
| Time Factors | 4 | 2022 | 1044 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 27 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 29 | 0.240 |
Why?
|
| Immunization | 1 | 2025 | 69 | 0.220 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 11 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 380 | 0.210 |
Why?
|
| Cluster Analysis | 1 | 2023 | 86 | 0.200 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 64 | 0.200 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 18 | 0.200 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 44 | 0.200 |
Why?
|
| Rotavirus Vaccines | 1 | 2022 | 53 | 0.200 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 44 | 0.190 |
Why?
|
| Pericarditis | 1 | 2022 | 11 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 118 | 0.190 |
Why?
|
| Myocarditis | 1 | 2022 | 14 | 0.190 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.190 |
Why?
|
| Narcolepsy | 1 | 2022 | 9 | 0.190 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.190 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 68 | 0.190 |
Why?
|
| Measles Vaccine | 1 | 2022 | 17 | 0.190 |
Why?
|
| Emergency Service, Hospital | 5 | 2023 | 381 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 15 | 0.190 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 36 | 0.190 |
Why?
|
| Infant, Premature | 1 | 2022 | 57 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 109 | 0.180 |
Why?
|
| Herpes Zoster | 1 | 2012 | 82 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 263 | 0.180 |
Why?
|
| Rubella | 1 | 2020 | 7 | 0.180 |
Why?
|
| Spatial Analysis | 1 | 2020 | 11 | 0.170 |
Why?
|
| Geography | 1 | 2020 | 39 | 0.170 |
Why?
|
| Pandemics | 4 | 2024 | 285 | 0.170 |
Why?
|
| Bursitis | 1 | 2020 | 4 | 0.170 |
Why?
|
| Shoulder Joint | 1 | 2020 | 5 | 0.170 |
Why?
|
| Telemedicine | 1 | 2024 | 182 | 0.170 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 42 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 31 | 0.170 |
Why?
|
| Eggs | 1 | 2020 | 8 | 0.170 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 26 | 0.170 |
Why?
|
| Influenza A virus | 1 | 2020 | 13 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 37 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2020 | 15 | 0.160 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 17 | 0.160 |
Why?
|
| Comorbidity | 3 | 2019 | 564 | 0.160 |
Why?
|
| Chemokines | 1 | 2019 | 6 | 0.160 |
Why?
|
| Child Development | 1 | 2020 | 53 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 52 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2020 | 378 | 0.150 |
Why?
|
| Croup | 1 | 2018 | 4 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2020 | 253 | 0.150 |
Why?
|
| Otitis Media | 1 | 2018 | 19 | 0.150 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 27 | 0.140 |
Why?
|
| African Americans | 1 | 2020 | 443 | 0.140 |
Why?
|
| Body Constitution | 1 | 2007 | 39 | 0.140 |
Why?
|
| Neoplasms | 1 | 2012 | 448 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 51 | 0.140 |
Why?
|
| Breast Diseases | 1 | 2007 | 18 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 627 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 244 | 0.140 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 29 | 0.140 |
Why?
|
| Prevalence | 2 | 2022 | 839 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 666 | 0.130 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 2 | 0.130 |
Why?
|
| Gestational Age | 1 | 2017 | 112 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 197 | 0.130 |
Why?
|
| Pesticides | 1 | 2016 | 8 | 0.130 |
Why?
|
| Pertussis Vaccine | 1 | 2016 | 14 | 0.130 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2016 | 6 | 0.130 |
Why?
|
| Diphtheria | 1 | 2016 | 13 | 0.130 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2016 | 12 | 0.130 |
Why?
|
| Tetanus | 1 | 2016 | 17 | 0.130 |
Why?
|
| Women's Health | 1 | 2007 | 197 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 533 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2020 | 1229 | 0.130 |
Why?
|
| Mammography | 3 | 2016 | 168 | 0.130 |
Why?
|
| Intellectual Disability | 1 | 2016 | 27 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 35 | 0.130 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 11 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2006 | 24 | 0.130 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2006 | 12 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 51 | 0.130 |
Why?
|
| Postpartum Period | 1 | 2016 | 79 | 0.120 |
Why?
|
| Maternal Exposure | 1 | 2016 | 66 | 0.120 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 53 | 0.120 |
Why?
|
| State Health Plans | 1 | 2005 | 33 | 0.120 |
Why?
|
| Age Distribution | 3 | 2012 | 239 | 0.110 |
Why?
|
| Prognosis | 3 | 2020 | 604 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 311 | 0.100 |
Why?
|
| Antipyretics | 1 | 2013 | 4 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 248 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 363 | 0.100 |
Why?
|
| Laboratories | 2 | 2021 | 19 | 0.090 |
Why?
|
| Immunization, Secondary | 2 | 2022 | 59 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 372 | 0.090 |
Why?
|
| Age Factors | 2 | 2025 | 884 | 0.080 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 480 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 538 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2025 | 1170 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 529 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2009 | 56 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2009 | 65 | 0.070 |
Why?
|
| SEER Program | 1 | 2016 | 94 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 537 | 0.060 |
Why?
|
| Insulin Glargine | 1 | 2013 | 8 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 9 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 3 | 0.050 |
Why?
|
| Reference Values | 1 | 2012 | 86 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 59 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2012 | 180 | 0.050 |
Why?
|
| Recurrence | 1 | 2012 | 165 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2023 | 135 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2015 | 273 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 32 | 0.050 |
Why?
|
| Patient Safety | 1 | 2022 | 38 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 92 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 251 | 0.050 |
Why?
|
| Anxiety | 1 | 2022 | 154 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 133 | 0.040 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 4 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 9 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 66 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 37 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 43 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 18 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 148 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 225 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 77 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 342 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 289 | 0.040 |
Why?
|
| Stroke | 1 | 2011 | 310 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1287 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 456 | 0.040 |
Why?
|
| Biomarkers | 1 | 2019 | 306 | 0.040 |
Why?
|
| Depression | 1 | 2022 | 487 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 87 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 144 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 27 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2011 | 707 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2006 | 53 | 0.030 |
Why?
|
| Bone Density | 1 | 2006 | 94 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 341 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 408 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 11 | 0.030 |
Why?
|
| Mother-Child Relations | 1 | 2013 | 13 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 23 | 0.030 |
Why?
|
| Registries | 1 | 2006 | 460 | 0.030 |
Why?
|
| Genotype | 1 | 2013 | 223 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 148 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 607 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 295 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2007 | 937 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 405 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1970 | 1 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1970 | 26 | 0.010 |
Why?
|
| Cobalt Isotopes | 1 | 1970 | 1 | 0.000 |
Why?
|
| Eye Manifestations | 1 | 1970 | 1 | 0.000 |
Why?
|
| Eye Diseases | 1 | 1970 | 6 | 0.000 |
Why?
|